Dongying Pharmaceutical's H-share full circulation has been approved by the China Securities Regulatory Commission. This allows 208 million domestic shares, representing 36.05% of the total share capital, to be converted into H-shares for listing. Following this approval, the company's tradable shares will significantly expand, increasing its market value in Hong Kong from HK$4.705 billion to HK$13.399 billion based on the closing price of the day. This expansion is expected to meet the thresholds for inclusion in Stock Connect and the Hang Seng Index. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON Company announcement regarding H-share full circulation approval and its impact on market value and index inclusion.